Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2: Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2)

Extension of the COVERALL (COrona VaccinE tRiAL pLatform) randomized trial showed noninferiority in antibody response of the third dose of Moderna mRNA-1273 vaccine (95.3% [95% confidence interval {CI}, 91.9%–98.7%]) compared to Pfizer-BioNTech BNT162b2 vaccine (98.1% [95% CI, 95.9%–100.0%]) in indi...

Descripción completa

Detalles Bibliográficos
Autores principales: Griessbach, Alexandra, Chammartin, Frédérique, Abela, Irene A, Amico, Patrizia, Stoeckle, Marcel P, Eichenberger, Anna L, Hasse, Barbara, Braun, Dominique L, Schuurmans, Macé M, Müller, Thomas F, Tamm, Michael, Audigé, Annette, Mueller, Nicolas J, Rauch, Andri, Günthard, Huldrych F, Koller, Michael T, Trkola, Alexandra, Epp, Selina, Amstutz, Alain, Schönenberger, Christof M, Taji Heravi, Ala, Kusejko, Katharina, Bucher, Heiner C, Briel, Matthias, Speich, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10077822/
https://www.ncbi.nlm.nih.gov/pubmed/37035486
http://dx.doi.org/10.1093/ofid/ofad150

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10077822/
https://www.ncbi.nlm.nih.gov/pubmed/37035486
http://dx.doi.org/10.1093/ofid/ofad150

Ejemplares similares